Stocktoria
Harmony Biosciences Holdings, Inc. HRMY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-08-19
Harmony Biosciences Holdings, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% |
| Operating margin | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% |
| Net margin | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% |
| FCF margin | 40.1% | 30.6% | 37.6% | 33.0% | 32.2% |
| Return on assets | 12.5% | 14.6% | 15.9% | 26.9% | 8.0% |
| Return on equity | 18.2% | 22.1% | 27.6% | 45.0% | 18.5% |
| Debt / equity | 0.19× | 0.27× | 0.41× | 0.48× | 1.03× |
| Current ratio | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 |
| Revenue growth | 21.5% | 22.8% | 32.9% | 43.4% | 91.2% |
Source: SEC EDGAR filings · CIK 0001802665 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.